A phase i ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 1, 2012, Pages 221-227

  Abbas, Richat ^a   Hug, Bruce A ^a   Leister, Cathie ^a   Gaaloul, Myriam El ^a   Chalon, Stephan ^a   Sonnichsen, Daryl ^a  

^a PFIZER INC   (United States)

Author keywords

Bosutinib (SKI 606); Dual Src Abl tyrosine kinase inhibitor; Pharmacokinetics; Safety

Indexed keywords

BOSUTINIB; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; CATHETER COMPLICATION; CONTROLLED STUDY; DIARRHEA; DISTRIBUTION VOLUME; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FOOD DRUG INTERACTION; HEART RATE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; ORTHOSTATIC HYPOTENSION; PHASE 1 CLINICAL TRIAL; POSITIONAL DIZZINESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADOLESCENT; ADULT; ANILINE COMPOUNDS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CHROMATOGRAPHY, LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOOD-DRUG INTERACTIONS; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; NITRILES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-ABL; QUINOLINES; SRC-FAMILY KINASES; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 84856689752     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1688-7     Document Type: Article

References (19)

1. SM Thomas JS Brugge 1997 Cellular functions regulated by Src family kinases Annu Rev Cell Dev Biol 13 513 609 9442882 10.1146/annurev.cellbio.13.1. 513 1:CAS:528:DyaK1cXisFSrsQ%3D%3D (Pubitemid 28034534)
2. E Avizienyte MC Frame 2005 Src and FAK signaling controls adhesions fate and the epithelial-to-mesenchymal transition Curr Opin Cell Bio 17 542 547 10.1016/j.ceb.2005.08.007 1:CAS:528:DC%2BD2MXhtVWnsb7K (Pubitemid 41267169)
3. TC Windham NU Parikh DR Siwak JM Summy DJ McConkey AJ Kraker GE Gallick 2002 Src activation regulates anoikis in human colon tumor cell lines Oncogene 21 7797 7807 12420216 10.1038/sj.onc.1205989 1:CAS:528:DC%2BD38XosVektb4%3D (Pubitemid 35398837)
4. MC Frame 2002 Src in cancer: deregulation and consequences for cell behaviour Biochim Biophys Acta 1602 114 130 12020799 1:CAS:528: DC%2BD38XjvVeitLs%3D (Pubitemid 34521791)
5. K Fizazi 2007 The roles of Src in prostate cancer Ann Oncol 18 1765 1773 17426060 10.1093/annonc/mdm086 1:STN:280:DC%2BD2snmvVWrtQ%3D%3D (Pubitemid 350119560)
6. J Homsi C Cubitt A Daud 2007 The Src signaling pathway: a potential target in melanoma and other malignancies Expert Opin Ther Targets 11 91 100 17150037 10.1517/14728222.11.1.91 1:CAS:528:DC%2BD28Xht1yisL7M (Pubitemid 46099755)
7. AM Pendergast 2002 The Abl family kinases: mechanisms of regulation and signaling Adv Cancer Res 85 51 100 12374288 10.1016/S0065-230X(02)85003-5 1:CAS:528:DC%2BD38XpsVyisrc%3D
8. D Srinivasan R Plattner 2006 Activation of Abl tyrosine kinases promotes invasion of aggressive breast cancer cells Cancer Res 66 5648 5655 16740702 10.1158/0008-5472.CAN-06-0734 1:CAS:528:DC%2BD28XltFyjt7g%3D (Pubitemid 43927117)
9. O Hantschel G Superti-Furga 2004 Regulation of the c-Abl and Bcr-Abl tyrosine kinases Nat Rev Mol Cell Biol 5 33 34 14708008 10.1038/nrm1280 1:CAS:528:DC%2BD2cXkt1SlsQ%3D%3D (Pubitemid 38089839)
10. JM Golas K Arndt C Etienne J Lucas D Nardin J Gibbons P Frost F Ye DH Boschelli 2003 SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice Cancer Res 63 375 381 12543790 1:CAS:528:DC%2BD3sXnt1Krsg%3D%3D (Pubitemid 36152495)
11. M Puttini AM Coluccia F Boschelli L Cleris E Marchesi A Donella-Deana S Ahmed S Redaelli R Piazza V Magistroni F Andreoni L Scapozza F Formelli C Gambacorti-Passerini 2006 In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl + neoplastic cells Cancer Res 66 11314 11322 17114238 10.1158/0008-5472.CAN-06-1199 1:CAS:528: DC%2BD28Xht1KnsLzI (Pubitemid 46009962)
12. A Vultur R Buettner C Kowolik W Liang D Smith F Boschelli R Jove 2008 SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells Mol Cancer Ther 7 1185 1194 18483306 10.1158/1535-7163.MCT-08-0126 1:CAS:528:DC%2BD1cXlvFamsrw%3D
13. Campone M, Bondarenko I, Brincat S, Epstein RJ, Munster PN, Dubois E, Martin EC, Turnbull K, Zacharchuk C (2007) Preliminary results of a phase 2 study of bosutinib (SKI-606), a dual Src/Abl kinase inhibitor, in patients with advanced breast cancer. Breast Cancer Res Treat 106: abstract 6062
14. Gambacorti-Passerini C, Pogliani EM, Baccarani M, Martinelli G, Kantarjian HM, Chandy M, Khoury HJ, Kim D, Brummendorf TH, Arkin S, Cortes J (2008) Bosutinib (SKI-606) demonstrates clinical activity and is well tolerated in patients with AP and BP CML and Ph + ALL. Blood 112: abstract 1101
15. Cortes J, Kantarjian H, Brümmendorf T, Khoury HJ, Kim D, Turkina A, Volkert A, Wang J, Arkin S, Gambacorti-Passerini C (2010) Safety and efficacy of bosutinib (SKI-606) in patients (pts) with chronic phase (CP) chronic myelogenous leukemia (CML) following resistance or intolerance to imatinib (IM). J Clin Oncol 28(Suppl 15): abstract 6502
16. Evans WE, Schentag JJ, Jusko WJ (1992) Principles of therapeutic drug monitoring, 3rd edn. Applied Therapeutics, Inc., Vancouver, WA
17. K Gough M Hutchison ON Keene B Byrom S Ellis LF Lacey J McKellar 1995 Assessment of dose proportionality: report from the statisticians in the pharmaceutical industry/pharmacokinetics UK joint working party Drug Inf J 29 1039 1048
18. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (2000) Guidance for industry. Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. August 2000. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm070246 pdf 2000 [cited 2011 May 11]; Available from: URL: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm070246.pdf
19. Abbas RA, Hug BA, Leister C, Burns J, Sonnichsen D (2011) Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects. J Clin Pharmacol. doi: 10.1177/0091270010387427